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Abstract
This paper reports the efficacy of emodepside/prazi-
quantel spot-on (Profender®, Bayer AG, Leverkusen,
Germany), a novel broadspectrum anthelmintic for
dermal application, against L4 larvae and immature
adult and adult stages of Ancylostoma tubaeforme in
cats. The formulation contains 2.14% (w/w) emodep-
side and 8.58% (w/v) praziquantel, with emodepside
being active against gastrointestinal nematodes and
praziquantel against cestodes. Five randomized, blind-
ed and controlled laboratory studies demonstrated
100% efficacy of emodepside/praziquantel spot-on
against mature A. tubaeforme and an efficacy of >95%
and >97%, respectively, against L4 larvae and imma-
ture adults (based on worm counts after necropsy) at
approximately the minimum proposed dose rate in cats
of 3.0 mg emodepside and 12.0 mg praziquantel/kg
body weight. No adverse reactions to the treatment
were observed. It is concluded that emodepside/prazi-
quantel spot-on is an effective and safe treatment
against infections with mature and immature A. tubae-
forme. Emodepside/praziquantel spot-on will consid-
erably facilitate the treatment of cats against nema-
todes and cestodes compared with orally administered
preparations.
Introduction
The hookworm Ancylostoma tubaeforme is endemic in
domestic cats throughout the world. Cats are infected
by skin penetration or ingestion of infective third-stage
(L3) larvae. The prepatent period of A. tubaeforme
ranges between 18 and 28 days depending on the
infection route (Bowman et al. 2002). The adult para-
sites are present in the small intestine, where they feed
on blood. While low to moderate infections cause mild
enteritis, heavy infections can lead to anemia and may
be fatal. Reported prevalence of A. tubaeforme in cats
from Europe and the Americas during recent years
ranges between 0 and 75%, with highest rates of infec-
tion in feral/stray cats (Table 1).
Little is known about the life cycle of A. tubaeforme
(Anderson 1992). Data from the literature and recent
findings indicate a zoonotic potential comparable to
that of the canine hookworm Ancylostoma caninum
(Prociv 1998; F. H. M. Borgsteede, personal communica-
tion).
Emodepside/praziquantel spot-on (Profender®) is a
novel broadspectrum anthelmintic product intended
for the topical treatment of cats with gastrointestinal
parasites, i.e., mature and immature nematodes (Toxo-
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cara cati, Toxascaris leonina, A. tubaeforme) and
mature cestodes (Dipylidium caninum, Taenia taeniae-
formis, Echinococcus multilocularis). Emodepside is a
semisynthetic derivative of PF1022A and belongs to a
new class of anthelmintic compounds, the cyclooc-
tadepsipeptides. PF 1022A was isolated from the
mycelial cake of a fungus (Mycelia sterilia) that was
found in the microflora on the leaves of the plant
Camellia japonica (Harder and von Samson-Himmel-
stjerna 2002). Emodepside is active against gastroin-
testinal nematodes, and in emodepside/praziquantel
spot-on is responsible for the efficacy against T. cati, T.
leonina, and A. tubaeforme. Emodepside acts presy-
naptically at the neuromuscular junction of nema-
todes, leading to an inhibition of pharyngeal pumping
and locomotion (Harder et al. 2003, 2005; Willson et al.
2003).
The present paper reports the findings of five laborato-
ry studies that evaluated the efficacy of emodepside/
praziquantel spot-on against mature and immature
stages of A. tubaeforme in naturally and experimental-
ly infected cats.
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Materials and methods
Three of the studies (A1–A3) were conducted to inves-
tigate the efficacy of emodepside/praziquantel spot-on
against mature A. tubaeforme in cats, and two studies
(B1, B2) that of emodepside/praziquantel spot-on
against immature (fourth stage larvae and immature
adults) A. tubaeforme in cats. The results of study B1
also allowed us to evaluate the efficacy of emodep-
side/praziquantel spot-on against mature A. tubae-
forme.
The investigations were performed as placebo-con-
trolled, blinded and randomized studies, conducted in
accordance with the VICH guideline 9 (VICH 2000b),
and followed the recommendations given in the VICH
guidelines 7  (VICH 2000a) and 20  (VICH 2001) as well
as the WAAVP guideline for evaluating the efficacy of
anthelmintics for dogs and cats (Jacobs et al. 1994).
The design of the studies is summarized in Tables 2 
and 3.
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Study animals
The cats used in the studies were either purposely bred
individuals from different breeding facilities or ani-
mals obtained from commercial kennels. The cats were
identified by transponder and/or ear tattoo and were
individually housed in cages. They were fed a commer-
cial cat food meeting dietary requirements, and were
provided with water ad libitum. All cats were acclima-
tized for a period of at least 7 days prior to the start of
the study.
None of the experimentally infected cats had received
any anthelmintic before and were negative for nema-
tode eggs prior to infection with A. tubaeforme. Cats in
studies A1–A3 were confirmed to be positive for A.
tubaeforme on the basis of fecal egg counts prior to
treatment.
Clinical observations
In all studies, cats were physically examined at least
twice before treatment and once after treatment. Addi-
tionally, all cats were observed for signs of impaired
health at least once daily. On the day of treatment, cats
were observed at approximately 0.5, 1, 2, 4, and 8 h
after treatment. Special attention was paid to the local
tolerance of the product at the observations conducted
post-treatment.
Infection
In two studies (A2, A3), cats naturally infected with A.
tubaeforme were used. The cats in these studies origi-
nated from the USA.
In studies A1, B1, and B2, cats were orally infected with
L3 larvae of A. tubaeforme (for details see Tables 2, 3).
The strains used in the studies had been isolated from
cats in Australia in 1995 (study A1), the Republic of
South Africa in 2000 (study B1), and the USA in 1995
(study B2).
Treatment
Cats of both sexes were randomly assigned to either
treatment or control groups. In all studies the cats were
treated once with either emodepside/praziquantel
spot-on or placebo.
In studies A1–A3 cats were treated after their infection
with A. tubaeforme had been confirmed. In study A1
where infection had been produced experimentally, the
cats were treated on day 34 post-infection.
In studies B1 and B2 the cats were treated either 7 or 14
days post-infection (study B1), or 7 or 11 days post-
infection (study B2). The earlier of the two administra-
tions in each study was aimed at the fourth-stage larvae
of A. tubaeforme, while the later one was applied to
evaluate the efficacy against immature adults.
In all studies, the concentration of emodepside in the
topically administered emodepside/praziquantel spot-
on was 2.14% (w/v), that of praziquantel 8.58% (w/v).
The composition of the test product was identical to
that of the product intended for use in the market. Dose
ranges in the cats on a per kilogram body weight basis
are given in Tables 2 and 3. Except for one study (A1)
using a somewhat higher dosage, the cats were treated
with approximately the proposed minimum dose of
emodepside/praziquantel spot-on of 3 mg emodep-
side and 12 mg praziquantel/kg body weight.
For application of emodepside/praziquantel spot-on or
placebo, the hair on the cat’s neck at the base of the
skull was parted until the skin was visible. The tip of a
pipette containing the appropriate amount of emodep-
side/praziquantel spot-on or the placebo was then
placed on the skin and the pipette’s content expelled
directly onto the cat’s skin.
Necropsy
Five to 10 days post treatment, the cats were eutha-
nized and subsequently necropsied (Tables 2, 3). At
necropsy, the digestive tract from stomach to rectum
was removed. The intestinal content and the results of
several mucosal strippings were washed over sieves
with apertures of 100 or 425 µm (studies A1–A3) or of
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50 or 75 µm (studies B1 and B2). Additionally, in stud-
ies B1 and B2, the intestines were soaked in pre-
warmed PBS or 0.9% saline for 3 h after the initial
mucosal stripping to enhance the release of worms
attached to the intestinal wall. All samples were ana-
lyzed for mature and immature worms and the recov-
ered specimens were counted and differentiated
according to stage and sex.
Efficacy determination and statistical analysis
In all studies, adequacy of infection in the control
group was assessed according to the methods suggest-
ed in VICH guidelines 7 and 20 (VICH 2000a, 2001). A
minimum of six animals with at least five worms each
in the control group was required. Additionally, the
intensity of infection was considered adequate when
the lower 95% confidence limit was >10% of the central
tendency (geometric mean if all worm counts in the
control group >0 or median if one or more worm
counts in the control group=0).
Percent efficacy for each treatment was calculated
according to VICH guideline 7 recommendations
(VICH 2000a) and the WAAVP guideline for evaluating
the efficacy of anthelmintics for dogs and cats (Jacobs
et al. 1994) as follows:
% Effectiveness (reduction)=(N2–N1)/N2¥100;
where N1=geometric mean nematode count for the
treatment group, and N2=geometric mean nematode
count for the control group.
Geometric means were calculated following transfor-
mation using a logarithmic method (averaging the
transformed values, and converting the average using
the antilog to represent a geometric mean). Because of
the occurrence of zero worm counts, 1 was added to
each count prior to transformation. Accordingly, 1 was
subtracted from the antilog value to represent the geo-
metric mean for each group. Because neither the actual
worm counts nor the logarithmically transformed
counts were distributed normally, the nonparametric
Wilcoxon rank sum test (two-tailed, using a=0.05) was
used to test for both gender and treatment group
(emodepside/praziquantel spot-on vs. placebo) effects.
Results
None of the cats from the five studies showed signs of a
local or systemic adverse reaction after treatment until
necropsy. The requirements for the adequacy of infec-
tion with A. tubaeforme were fulfilled in all studies
except study A2. In this study only four cats in the con-
trol group had five or more worms, but two further cats
had four worms each. Thus the control group was short
of two worms. Since this result was very close to the
requirements and the lower 95% confidence limit was
>10% of the geometric mean the infection was consid-
ered to be adequate.
In the studies (A1–A3, B1) investigating the efficacy of
emodepside/praziquantel spot-on against mature A.
tubaeforme, the treatment was totally effective in all
treated cats, removing 100% of the worms in the treat-
ment group (Table 4).
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One of the two studies (B1) investigating the efficacy of
emodepside/praziquantel spot-on against immature A.
tubaeforme, demonstrated an efficacy of >95% against
L4 larvae and of >97% against immature adults. The
second study (B2) demonstrated 100% efficacy against
both stages (Tables 5, 6).
All differences between treatment and control groups
were statistically significant (for P-values see Tables
4–6).
Discussion
Four studies demonstrated 100% efficacy of emodep-
side/praziquantel spot-on against mature A. tubae-
forme at approximately the minimum proposed dose
rate of 3.0 mg emodepside and 12.0 mg praziquan-
tel/kg body weight (studies A2, A3, B1), or a somewhat
higher dose rate between 3.1–4.6 mg emodepside and
12.2–18.4 praziquantel/kg body weight (study A1).
Additionally, two studies (B1, B2) demonstrated a high
efficacy of emodepside/praziquantel spot-on at
approximately the minimum proposed dose rate
against L4 larvae (efficacy >95%) and immature adults
(efficacy >97%) of A. tubaeforme. No adverse reactions
to the treatment were observed in the cats. It can there-
fore be concluded that emodepside/praziquantel spot-
on is an effective and safe treatment against L4 larvae,
immature adult and adult stages of A. tubaeforme.
It has become common veterinary practice to simulta-
neously treat cats for infections with gastrointestinal
cestodes and nematodes. Several combination pro-
ducts for such treatment are available for oral adminis-
tration but this formulation type can be difficult to
apply, particularly in non-cooperative cats. Therefore,
dermal administration of anthelmintics, as a more con-
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venient and less stressful way of application, may help
to increase the compliance of owners and veterinarians
to deworm cats. Use of emodepside/praziquantel spot-
on will considerably facilitate the anthelmintic treat-
ment of cats and should thus increase the likelihood of
successful treatment taking place.
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